NEW YORK, NY, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB: TAUG) (OTCQB: TAUGD) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that the Company has generated a quarterly net profit of $166,788 for its 1st Fiscal Quarter of 2019 (Period Ending: June 30, 2018). On a fully diluted basis, this translates to an Earnings Per Share (“EPS”) of $0.003 (“three tenths of one penny”).
As a Corporate policy, moving forward, the Company plans to report the financial results generated during each future Quarter as well as Year End. These results will be reported either via press release or on Form 8-K (or both). There can be no guarantee that the Company will generate any Quarterly profits in the future.
For a full report on the Company’s financial results for the most recent quarter, please review Tauriga’s Form 10-Q for its 1st Fiscal Quarter of 2019 (Period: April 1, 2018 - June 30, 2018).
About Tauriga Sciences, Inc.
Tauriga Sciences, Inc. (OTCQB: TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities/equity investments. The Company is currently evaluating potential acquisition candidates, as previously disclosed, to create lasting shareholder value. Additionally, the Company is working diligently to identify potential opportunities to generate revenue and leverage its considerable resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
cell # (917) 796 9926